Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (20128)	3/25/1999 9:00:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Sorry but that info is erroneous. It is actually from January 1999. But if we take the current short interest which is over 6 million shares and divide it by the current daily average (ignoring the skewed monthly average after those 2 high volume days) we are probably in the top ten. For example, if we now average 500,000 shares traded per day, with a short interest of 6M it will take 12 trading days to cover. I know they look at the monthly averages but in Vivus' case we had an unusually high 2 days of volume after the female SD announcement which brings up the monthly average to 1.6M which is not a true picture of our daily trading.

To: VLAD who wrote (20128)	3/26/1999 10:52:00 AM
From: John M. Gelnieau	Read Replies (1) \| Respond to of 23519

Hey VLAD, WLA's Rezulin caused 28 deaths, over the last two years as I understand the news, and the hard hammer of FDA having to take a serious look to evaluate risk/reward of prescribing this drug. From the news report I heard there seems to be some question as to its life saving benefit since so few prescriptions have been for life or death situations. All this time you couldn't understand FDA position with the big V with over 400 deaths in first year. Well, maybe life enhancing is of more value than life saving? :(